Synthaverse

Synthaverse EBITDA per Share

The EBITDA per Share of Synthaverse (SVE.WA) as of Oct 24, 2026 is -0.27 PLN. In the previous year, EBITDA per Share was 0.25 PLN — a change of -207.35% (lower).

EBITDA per Share

-0.27PLN

YoY

-207.35%

Last updated:

EBITDA per Share of Synthaverse is 2025 -0.27 PLN. EBITDA per Share of Synthaverse was 2024 0.25 PLN. It decreases by -207.35% lower compared to the previous year.

The Synthaverse EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.57 PLN
Jan 1, 2019
0.09 PLN
Jan 1, 2020
0.14 PLN
Jan 1, 2021
0.15 PLN
Jan 1, 2022
0.19 PLN
Jan 1, 2023
0.18 PLN
Jan 1, 2024
0.25 PLN
Jan 1, 2025
-0.27 PLN
The Synthaverse EBITDA per Share history
YEAREBITDA per ShareYoY
-0.27PLN-207.35%
0.25PLN+43.44%
0.18PLN-9.13%
0.19PLN+26.16%
0.15PLN+12.61%
0.14PLN+48.76%
0.09PLN-116.14%
-0.57PLN-773.57%
0.08PLN-113.45%
-0.63PLN-16.42%
-0.75PLN-1,265.40%
0.06PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synthaverse Stock analysis

What does Synthaverse do? Biomed Lublin is a Polish company that has been active in the production of serums and vaccines since 1950. It has grown to become a leading producer of biological substances and medical devices in Eastern Europe. The company was originally a state institution for the development of animal vaccines but was privatized after the political changes in the late 1980s. Since 2002, it has been listed on the Warsaw Stock Exchange and has expanded its focus. Biomed Lublin operates in four main areas: veterinary medicine, human medicine, diagnostics, and laboratory equipment. It has a strong reputation in the veterinary medicine field, offering vaccines and diagnostics for livestock and pets. The company is also involved in human medicine, producing vaccines and diagnostics exclusively in Poland. In the diagnostics field, Biomed Lublin has developed and manufactured a variety of test kits used in medical diagnostics. It also offers laboratory equipment such as microscopes, pipettes, and centrifuges for medical and biological testing in hospitals and laboratories. Overall, Biomed Lublin aims to continue expanding its presence in the biotech industry in Eastern Europe and providing high-quality and effective diagnostic and therapeutic solutions to improve the health of both humans and animals. Synthaverse is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synthaverse stock

EBITDA per Share of Synthaverse is -0.27 PLN in 2025.

EBITDA per Share of Synthaverse changed from 0.25 PLN to -0.27 PLN, representing a -207.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Synthaverse since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Synthaverse

All Key Metrics — Synthaverse